Pacific Biosciences of California, Inc.
PACB
$1.38
$0.129.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.35% | -23.99% | -23.19% | 2.14% | 29.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.35% | -23.99% | -23.19% | 2.14% | 29.24% |
| Cost of Revenue | -15.70% | -17.83% | -22.19% | 6.14% | 37.82% |
| Gross Profit | -21.38% | -38.09% | -25.65% | -6.57% | 12.13% |
| SG&A Expenses | -5.49% | 2.98% | 7.48% | 2.16% | 10.40% |
| Depreciation & Amortization | 1,674.80% | 2,513.38% | 236.60% | 1,253.66% | 1,853.87% |
| Other Operating Expenses | 47.44% | 47.44% | -70.95% | -- | -- |
| Total Operating Expenses | 52.10% | 58.22% | -9.48% | 1.34% | 14.97% |
| Operating Income | -92.68% | -110.89% | 0.61% | -0.90% | -8.00% |
| Income Before Tax | -27.80% | -113.33% | 2.71% | -23.50% | -29.01% |
| Income Tax Expenses | 100.43% | 100.12% | 102.77% | 93.29% | -- |
| Earnings from Continuing Operations | -31.46% | -121.54% | -1.02% | -27.54% | -25.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.46% | -121.54% | -1.02% | -27.54% | -25.43% |
| EBIT | -92.68% | -110.89% | 0.61% | -0.90% | -8.00% |
| EBITDA | 21.52% | 10.11% | 8.04% | 8.94% | -0.42% |
| EPS Basic | -19.63% | -100.76% | 5.92% | -13.89% | -10.13% |
| Normalized Basic EPS | -77.47% | -95.61% | 5.33% | 8.70% | 6.42% |
| EPS Diluted | -19.47% | -100.92% | 5.87% | -14.33% | -10.55% |
| Normalized Diluted EPS | -75.39% | -93.47% | 7.43% | 8.70% | 6.42% |
| Average Basic Shares Outstanding | 8.35% | 8.00% | 8.25% | 11.16% | 12.78% |
| Average Diluted Shares Outstanding | 10.60% | 10.30% | 10.60% | 11.16% | 12.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |